Systemic Inflammatory Response Syndrome Treatment Market to Reach US$ 21.36 Bn by 2030

Spread the love

Precedence Research’s latest report on the global systemic inflammatory response syndrome treatment market provides an analysis for the period of 2017 to 2030, wherein, 2020 is the base year, 2017 and before is historical data, and 2021 to 2030 is the forecast period.

The global systemic inflammatory response syndrome treatment market size was valued at US$ 10.49 Billion in 2020 and is projected to reach US$ 21.36 Billion by 2030, rising at a market growth (CAGR) of 7.37% during the forecast period.

Precedence Research provides an in-depth analysis of market size, share analysis, Industry growth, market valuation, market dynamics which includes drivers, restraints, opportunities, trends, challenges, market segmentation, competitive landscape, regional and country breakdowns, and strategies for systemic inflammatory response syndrome treatment market. The study reviews the global industry by-products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context, and more.

The report comprises a detailed value chain analysis, which provides a comprehensive view of this market. The Porter’s Five Forces model for the global market has also been included to help understand the competitive landscape. The study covers market attractiveness analysis, wherein resin types are benchmarked based on their market value, growth rate, and general attractiveness.

Download FREE SAMPLE PAGES before Purchase

Growth Factors

Increase in frequency of Systemic Inflammatory Response Syndrome, prominence of Systemic Inflammatory Response Syndrome Treatment to remain strong for urinary tract infection treatment are among major factors boosting growth of the global industry. Additionally, technological advancements and integration of latest technologies is fueling growth of the systemic inflammatory response syndrome treatment market worldwide. Moreover, high investment by major players in research and development is having positive impact on the growth of global industry. Further, increased focus on the improvement of healthcare infrastructure in developing regions and growing awareness regarding early diagnosis are other factors to boost growth of the global market during the forecast time frame.

One of the key factors for assessing post-surgical complications and end-organ dysfunction is systemic inflammatory response syndrome. Syndrome progression is linked to lengthy hospital stays, high incidence of multiple organ dysfunction, and elevated morbidity.

In cardiac surgery, Systemic Inflammatory Response Syndrome is among the popular post-operative complications, leading to organ failure or even death. It is expected that the prevalence of Systemic Inflammatory Response Syndrome among pediatric patients will increase in the near future.

The University Of Colorado School Of Medicine released an article claiming that 40,356 pediatric patients met inclusion requirements out of 56,210 visits to emergency departments over a 1-year study period. Patients with Systemic Inflammatory Response Syndrome vital signs accounted for 92.8 per cent of all visits with fever > 38.5 ° C among the sample population included.

Apart from therapies, the development of numerous pipeline drugs is also led by extensive efforts supported by central and private funding. For example, Adrecizmab, which is considered efficient for the treatment of septic shock, was introduced by Adrenomed AG. The medication is also effective in preventing vascular damage and keeping ideal vascular functions intact. Thus, Therapeutics and pipeline drugs, driven by efficiency, are projected to maintain demand in the treatment market for systemic inflammatory response syndrome in the future.

Report Highlights

  • Based on product type, autoimmune diseases reported largest revenue in 2020. This is accredited to high incidence of autoimmune disorders.
  • On the basis of application, hospital & ambulatory surgical centers accounted for the weighty share in the target industry. This is due to availability of latest infrastructure.
  • GlaxoSmithKline and AstraZeneca are major companies operating in the global systemic inflammatory response syndrome treatment market.

Key Players of the global systemic inflammatory response syndrome treatment market are:

  • GlaxoSmithKline
  • AstraZeneca
  • CytoSorbents Corporation
  • Cardinal Health
  • Asahi Kasei
  • ConvaTec
  • CHIESI Farmaceutici
  • Smith & Nephew

Segments Covered in the Report:

Market Segment

By Product Type

  • Urinary Tract Infection (UTI)
  • Autoimmune Diseases
  • Meningitis
  • Pneumonia
  • Others

By Application

  • Specialty Clinics
  • Hospital & Ambulatory Surgical Centers
  • Others

Regional Segment

  • North America (United States, Canada)
  • Europe (Germany, France, UK,  Italy, Russia, and Rest of Europe)
  • Asia-Pacific (China, Japan, India, Southeast Asia, Korea, and Rest of Asia Pacific)
  • Latin America (Brazil and the Rest of Latin America)
  • The Middle East and Africa (GCC, North Africa, South Africa, and Rest of the Middle East & Africa)

Purchase this Market Research Report @

About Us:

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semiconductors, chemicals, automotive, and among different ventures present globally.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333


Steve Robber

My name is Steve Robber, I’m the Owner of Market Stats News. Steve has served in many positions at various organizations for the past seven years. Currently he is an Author at Finance.Yahoo. Contact us for a free news publication, we look forward to speaking with you!

View all posts by Steve Robber →

Leave a Reply

Your email address will not be published. Required fields are marked *